ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings
  • Abstract Number: 0408 • ACR Convergence 2023

    The Role of Synovial Biopsy in Evaluating Rheumatoid Arthritis Acitivity in Patients: Findings from a Study of 30 Patients Treated with Adalimumab

    Rui Wu and YIlin Peng, the first affilated hospital of Nanchang University, Nanchang, China

    Background/Purpose: Rheumatoid arthritis(RA)is a chronic autoimmune disease that is characterized by inflammation and destrction of synovial jionts  which result in high disabilty. Treat-to-Target is critical…
  • Abstract Number: 0417 • ACR Convergence 2023

    The Role of Rheumatoid Arthritis Flare in the Risk of Alzheimer’s Disease and Related Dementias: A Population-based Cohort Study

    Chanakya Kodishala1, Tina Gunderson2, Edward Lovering2, Rakesh Kumar2, Cynthia Crowson2, John Davis2 and Elena Myasoedova2, 1Mayo Clinic Rochester Minnesota, Rochester, MN, 2Mayo Clinic, Rochester, MN

    Background/Purpose: Patients with rheumatoid arthritis (RA) have increased risk for Alzheimer's disease and related dementias (AD/ADRD). Recent studies have reported an association between RA disease…
  • Abstract Number: 0420 • ACR Convergence 2023

    Associations and Mortality Impact of Machine Learning-derived Quantitative Computed Tomography Parenchymal Lung Features in Rheumatoid Arthritis and non-RA Comparators in a Multicenter Prospective Cohort of Smokers

    Gregory McDermott1, Keigo Hayashi1, Matthew Moll1, Michael Cho1, Kazuki Yoshida1, Tracy J. Doyle1, Gregory Kinney2, Paul Dellaripa3, Zachary Wallace4, Elizabeth Regan5, Gary Hunninghake1, Edwin Silverman1, Samuel Ash1, Raul San Jose Estepar1, George Washko1 and Jeffrey Sparks6, 1Brigham and Women's Hospital, Boston, MA, 2University of Colorado Denver, Denver, CO, 3Brigham and Women's Hospital, Boston, MA, 4Massachusetts General Hospital, Newton, MA, 5National Jewish Health, Denver, CO, 6Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA

    Background/Purpose: Quantitative computed tomography (QCT) methods have been developed to automatically quantify parenchymal lung features on chest CT imaging. There have been limited investigations of…
  • Abstract Number: 0424 • ACR Convergence 2023

    Real-World Effectiveness of Upadacitinib in Patients with Moderate/Severe Rheumatoid Arthritis: 6-Month Data from the Observational UPHOLD Study

    Andrew Östör1, Eugen Feist2, Prodromos Sidiropoulos3, Jérôme Avouac4, Martin Rebella5, Rajaie Namas6, Bruno Frediani7, Song-Chou Hsieh8, Tianming Gao9, Nasser Khan10, Sander Strengholt11, Ivan Lagunes-Galindo10 and Susan Attar12, 1Monash University & Emeritus Research; Australian National University, Melbourne, Australia, 2Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, 3Faculty of Medicine, University of Crete, Heraklion, Greece, 4Service de Rhumatologie, Hôpital Cochin, AP-HP.Centre – Université Paris Cité, Paris, France, 5Departamento de Medicina, Facultad de Medicina, Universidad de la República; Unidad de Enfermedades Autoinmunes Sistémicas, MUCAM, Montevideo, Uruguay, 6Medical Subspecialties Institute, Division of Rheumatology, Cleveland Clinic Abu Dhabi, Abu Dhabi, United Arab Emirates, 7Santa Maria alle Scotte General Hospital, Siena, Italy, 8National Taiwan University Hospital, Taipei, Taiwan, 9AbbVie, Inc., North Chicago, IL, 10Pharmacovigilance and Patient Safety, AbbVie, Inc., North Chicago, IL, 11AbbVie B.V., Mijdrecht, Utrecht, Netherlands, 12King Abdulaziz University, Jeddah, Saudi Arabia

    Background/Purpose: The efficacy and safety of upadacitinib (UPA), an oral reversible Janus kinase inhibitor, have been shown in patients (pts) with moderate/severe RA in the…
  • Abstract Number: 0368 • ACR Convergence 2023

    Surveying Psychological Resilience and Pain in a Cross-Section of JIA Patients

    Daniella Schocken and Tracy Ting, Cincinnati Children's Hospital Medical Center, Cincinnati, OH

    Background/Purpose: Pain trajectories vary in JIA, with some patients developing chronic pain over the course of their illness. Adaptation and recovery under stressful or traumatic…
  • Abstract Number: 0374 • ACR Convergence 2023

    Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry

    Bashayer Alnuaimi1, Michelle Batthish2, Roberta A Berard3, Gilles Boire4, Sarah Campillo1, Amieleena Chhabra5, Julie Couture6, Paul Dancey7, Brian Feldman8, Tommy Gerschman9, Julie Herrington10, Kristin Houghton11, Adam Huber12, Claire LeBlanc1, Lillian Lim13, Jean-Philippe Proulx-Gauthier6, Heinrike Schmeling14, Rosie Scuccimarri1, Lori Tucker15, Jaime Guzman15, Gaëlle Chédeville1 and For The CAPRI Registry Investigators16, 1McGill University Health Center, Montreal, QC, Canada, 2McMaster Children's Hospital, Hamilton, ON, Canada, 3Children's Hospital - London Health Sciences Centre, London, ON, Canada, 4Université de Sherbrooke, Sherbrooke, QC, Canada, 5British Columbia Hospital, Vancouver, BC, Canada, 6CHU de Quebec- Universite Laval, Quebec City, QC, Canada, 7Memorial University of Newfoundland, St. John's, NL, Canada, 8The Hospital for Sick Children, Toronto, ON, Canada, 9British Columbia Children's Hospital, Burnaby, BC, Canada, 10McMaster University, Hamilton, ON, Canada, 11British Columbia University, Vancouver, BC, Canada, 12IWK Health Centre, Halifax, NS, Canada, 13University of Alberta, Edmonton, AB, Canada, 14University of Calgary, Calgary, AB, Canada, 15British Columbia Children's Hospital, Vancouver, BC, Canada, 16CAPRI, Montreal, QC, Canada

    Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…
  • Abstract Number: 0313 • ACR Convergence 2023

    The Influence of Pain Catastrophizing on Pain and Function After Knee Arthroplasty for Osteoarthritis

    Diana, Xin Hui Chan1, Seyed Ehsan Saffari2, Steven, Bak Siew Wong3, Seng Jin Yeo1, Vikki Wylde4, Julian Thumboo1 and Ying Ying Leung1, 1Singapore General Hospital, Singapore, Singapore, 2Center for Quantitative Medicine, Duke-NUS Medical School, National University of Singapore, Singapore, Singapore, 3Sengkang General Hospital, Singapore, Singapore, 4University of Bristol, Bristol, United Kingdom

    Background/Purpose: To evaluate the association between pre-operative pain catastrophizing and pain and function outcomes up to one year after knee arthroplasty. Methods: We used data…
  • Abstract Number: 0370 • ACR Convergence 2023

    Clinical Disease Manifestations Associated with TNF Inhibitor Non-Response in Juvenile Spondyloarthritis

    Melissa Oliver1, Kelly Mosesso2, Pamela F. Weiss3, Robert Colbert4, Matthew Stoll5 and Hemalatha Srinivasalu6, 1Indiana University, Indianapolis, IN, 2Indiana University School of Medicine, Indianapolis, IN, 3Children's Hospital of Philadelphia, Philadelphia, PA, 4NIH/NIAMS, Bethesda, MD, 5University of Alabama at Birmingham, Birmingham, AL, 6Children's National Hospital, Washington, DC

    Background/Purpose: Tumor necrosis factor inhibitors (TNFi) are effective in children with juvenile spondyloarthritis (JSpA) and generally represent the first-line choice for biologic therapy. However, not…
  • Abstract Number: 0381 • ACR Convergence 2023

    Disease Burden, Patient Experiences, and Unmet Needs in Refractory Rheumatoid Arthritis: Insights from 20 Years of Real-World Data

    Kristin Wipfler1, Bobby Kwanghoon Han2, Sofia Pedro3, Urbano Sbarigia4, Federico Zazzetti5, Anna Sheahan6, Iris Lin7, Patti Katz8, Evo Alemao9 and Kaleb Michaud10, 1FORWARD, The National Databank for Rheumatic Diseases, Omaha, NE, 2University of Washington, Seattle, WA, 3Forward, The National Databank for Rheumatic Diseases, Wichita, KS, 4Janssen Pharmaceutica, Beerse, Belgium, 5Janssen Research & Development, LLC, Spring House, PA, 6Janssen, Raleigh, NC, 7Janssen, Horsham, PA, 8University of California San Francisco, San Rafael, CA, 9Janssen Pharmaceuticals, New Hope, PA, 10University of Nebraska Medical Center, Omaha, NE

    Background/Purpose: Despite major advances in RA treatment, a substantial number of patients (estimated at 6-21%1) are refractory to multiple advanced therapies. Well-defined refractory RA (reRA)…
  • Abstract Number: 0306 • ACR Convergence 2023

    Fitbit Is a Valid and Reliable Physical Activity Monitor in Idiopathic Inflammatory Myopathy

    Akanksha Sharma1, shiri keret2, Raisa Lomanto Silva3, Tanya Chandra4, Joel Levin5, Siamak Moghadam-Kia3, Chester V. Oddis6 and Rohit Aggarwal6, 1UPMC Mercy Hospital, Pittsburgh, PA, 2Bnai Zion, Atlit, Israel, 3University of Pittsburgh Medical Center, Pittsburgh, PA, 4Georgetown University Hospital, Washington, DC, 5University of Pittsburgh, Katz Graduate School, Pittsburgh, PA, 6University of Pittsburgh, Pittsburgh, PA

    Background/Purpose: Idiopathic inflammatory myopathies (IIM, myositis) are a systemic autoimmune disease leading to debilitating muscle weakness and significant limitations in daily activities. Physical activity monitor…
  • Abstract Number: 0391 • ACR Convergence 2023

    Biologic Use Regulates the Impact of Inflammation on Ischemic Cardiovascular Risk in Rheumatoid Arthritis

    George Karpouzas1, Sarah Ormseth2, Piet Van Riel3, Elena Myasoedova4, Miguel A Gonzalez-Gay5, Alfonso Corrales6, Solbritt Rantapää-Dahlqvist7, Petros Sfikakis8, Patrick Dessein9, Linda Tsang9, Carol Hitchon10, Hani El Gabalawi10, Virginia Pascual Ramos11, Irazú Contreras Yañez12, Iris Colunga13, Dionicio A. Galarza-Delgado13, José Ramón Azpiri-López13, Silvia Rolefstad14, Anne Grete Semb15, Durga P Misra16, Ellen Margrethe Hauge17 and GEORGE KITAS18, 1Harbor-UCLA Medical Center, Torrance, CA, 2The Lundquist Institute, Torrance, CA, 3Radboud University Medical Center, Drunen, Netherlands, 4Mayo Clinic, Rochester, MN, 5IDIVAL and School of Medicine, UC, Santander; Department of Rheumatology, IIS-Fundación Jiménez Díaz, Madrid, Santander, Spain, 6Rheumatology Department, Immunopathology Group, Hospital Universitario Marqués de Valdecilla-IDIVAL, Santander, Spain, 7Department of Public Health and Clinical Medicine/Rheumatology, Umeå University, Umeå, Sweden, 8National Kapodistrian University of Athens Medical School, Athens, Greece, 9University of Witwatersrand, Johannesburg, South Africa, 10University of Manitoba, Winnipeg, MB, Canada, 11Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, 12Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 13Hospital Universitario UANL, Monterrey, Mexico, 14Diakonhjemmet Hospital, Oslo, Norway,, Oslo, Norway, 15Preventive Cardio-Rheuma clinic, Dept Rheum, Diakonhjemmet Hospital, Oslo, Norway, 16Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS), Lucknow, India, 17Aarhus University Hospital, Aarhus, Denmark, 18The Dudley Group NHS Foundation Trust, Birmingham, United Kingdom

    Background/Purpose: Chronic inflammation contributes to enhanced cardiovascular risk in rheumatoid arthritis (RA). Biologic disease modifying antirheumatic drugs (bDMARDs) control inflammation in many conventional synthetic DMARD…
  • Abstract Number: 0394 • ACR Convergence 2023

    Higher Intakes of Red Meat Are Associated with an Increased Risk of Developing Seropositive but Not Seronegative Rheumatoid Arthritis – Results from a Nested Case-Control Study

    Rebecka Teresia Bäcklund1, Isabel Drake1, Ulf Bergström1, Michele Compagno2, Emily Sonestedt1 and Carl Turesson1, 1Lund University, Malmö, Sweden, 2Lund University, Lund, Sweden

    Background/Purpose: Healthy eating habits might prevent the development of rheumatoid arthritis (RA). We aimed to examine the relation between adherence to dietary recommendations and the…
  • Abstract Number: 0399 • ACR Convergence 2023

    Differential Synovial Tissue Enrichment of Oxylipins and Their Mediators Across Rheumatoid Arthritis Trajectory

    Simone Perniola1, Jessica Murillo-Saich2, Barbara Tolusso3, Clara Di Mario3, Marco Gessi4, Dario Bruno5, Luca Petricca6, Maria Rita Gigante6, Elisa Gremese5, Monica Guma7 and Stefano Alivernini8, 1Division of Clinical Immunology – Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 2Department of Medicine, University of California San Diego, La Jolla, CA, 3Immunology Research Core Facility – Gemelli Science and Technology Park (GSTeP) - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 4Division of Pathology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 5Division of Rheumatology, Institute of Rheumatology and Affine Sciences, School of Medicine, Catholic University of the Sacred Heart, Roma, Italy, 6Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy, 7University of California San Diego, La Jolla, CA, 8Immunology Research Core Facility, Gemelli Science and Technology Park, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy; Division of Rheumatology - Fondazione Policlinico Universitario A. Gemelli IRCCS - Università Cattolica del Sacro Cuore, Rome, Italy

    Background/Purpose: Synovial membrane represents the target tissue of Rheumatoid Arthritis (RA) inflammation. Our study aimed to perform a comprehensive quantification of oxylipins and their precursors…
  • Abstract Number: 0401 • ACR Convergence 2023

    Resolution of Swollen Joint Count Is an Important Clinical Objective in Early Rheumatoid Arthritis : Analysis of the UCLouvain Brussels ERA Cohort and Comparison with the Remission Composite Index

    Francesco Natalucci1, clement triaille2, Emilie Sapart2, Laura BRICMAN3, Cécile VAN MULLEM2, Charlotte Desmet2, Stéphanie DIERCKX4, Marie DOYEN2, Tatiana Sokolova5, Aleksandra AVRAMOVSKA3 and Patrick Durez2, 1UCLouvain University, Sermoneta, Italy, 2Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Rheumatology, Brussels, Belgium, 3Rheumatology, Cliniques Universitaires Saint-Luc – Université catholique de Louvain (UCLouvain) – Institut de Recherche Expérimentale et Clinique (IREC), Brussels, Belgium, 4CHU UCL Namur, Rheumatology, Mont-Godinne, Belgium, Mont Godinne, Belgium, 5Université Catholique de Louvain, Brussels, Belgium

    Background/Purpose: Rheumatoid Arthritis is a chronic autoimmune disease characterized by persistent joint inflammation. According to international guidelines, the treatment target should aim to reach the…
  • Abstract Number: 0330 • ACR Convergence 2023

    Patient-Reported Experiences and Comorbidities in Patients with IgG4-Related Disease with and Without Pancreatic Involvement

    Liam Harvey1, Guy Katz2, Yasmin Hernandez-Barco2, Ana Fernandes2, Aubree McMahon2, Grace McMahon2, Isha Jha2, Zachary Wallace3, Cory Perugino2 and John Stone4, 1Frank H. Netter School of Medicine at Quinnipiac University, New Haven, CT, 2Massachusetts General Hospital, Boston, MA, 3Massachusetts General Hospital, Newton, MA, 4Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA

    Background/Purpose: IgG4-Related Disease (IgG4-RD) is a systemic immune-mediated disease that commonly involves the pancreas in the form of autoimmune pancreatitis (AIP). Despite being one of…
  • « Previous Page
  • 1
  • …
  • 191
  • 192
  • 193
  • 194
  • 195
  • …
  • 2425
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology